Skip to contentC
Chemed Corp
C
CHEChemed Corp Q3 2025 · 10-Q
Revenue$624.90M$624.90M+59.7% vs Q3 2024 Net Income$64.24M$64.24M−15.2% vs Q3 2024 EPS Diluted$4.46$4.46−10.8% vs Q3 2024 Operating Income$74,750,000−18.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Chemed Corp · CIK 19584 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$66,030,000−14.2% Margins · derivedOperating margin12.0%−11.6 pt vs Q3 2024
Net margin10.3%−9.1 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 31, 2025 · 31 d after period end